MétaCan
Menu
Back to cohort
Record W4413364870 · doi:10.1016/j.ctrv.2025.103015

Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life

2025· review· en· W4413364870 on OpenAlexfundno aff
Marco Airoldi, Susana Roselló, Noelia Tarazona, Marisol Huerta, Leticia Pérez‐Santiago, Tania Fleitas, Vicente Pla‐Martí, Alberto Puccini, Desamparados Roda, Andrés Cervantes

Bibliographic record

VenueCancer Treatment Reviews · 2025
Typereview
Languageen
FieldMedicine
TopicColorectal Cancer Surgical Treatments
Canadian institutionsnot available
FundersMSD ItaliaGenentechFoundation MedicineSierra OncologyDaiichi Sankyo EuropeServierEuropean Society for Medical OncologyFibroGenAstellas PharmaFundación Científica Asociación Española Contra el CáncerSirtex MedicalNateraSeagenSociedad Española de Oncología MédicaBeiGeneINCLIVA Instituto de Investigación SanitariaGlaxoSmithKlineG1 TherapeuticsTakeda Pharmaceuticals U.S.A.Instituto de Salud Carlos IIIAmgenPfizerLes Laboratories Pierre FabreAstraZenecaEli Lilly and CompanyBristol-Myers Squibb
KeywordsMedicineQuality of life (healthcare)Colorectal cancerBalance (ability)CancerIntensive care medicineGerontologyOncologyInternal medicinePhysical therapyNursing

Abstract

fetched live from OpenAlex

The treatment of locally advanced rectal cancer (LARC) has undergone a significant evolution in recent years, shifting toward more selective strategies that balance oncological outcomes with quality of life (QoL) preservation. Total neoadjuvant treatment (TNT) has improved local control and reduced distant metastases, but its long-term toxicities have sparked growing interest in treatment de-escalation strategies aimed at minimizing adverse effects while maintaining efficacy. This review focuses on the therapeutic advancements for LARC, analysing both established standards and emerging innovations. We discuss the increasing adoption of organ-preserving approaches, particularly the Watch-and-Wait (WW) strategy for patients achieving a clinical complete response (cCR), and potentially the selective omission of radiotherapy in well-defined cases. Additionally, we explore and examine less invasive surgical techniques that preserve function without compromising cure rates. Beyond standard treatment approaches, we highlight the role of immunotherapy, particularly its breakthrough efficacy in LARC with deficient mismatch repair/microsatellite instability (dMMR/MSI), leading to the concept of immune-ablation: achieving complete tumor regression while sparing patients from chemotherapy, radiotherapy, and surgery. Ongoing research is investigating immunotherapy's potential role also in proficient mismatch repair/microsatellite stable (pMMR/MSS) LARC. Finally, we discuss emerging predictive biomarkers, such as circulating tumor DNA (ctDNA) and radiomics, which might refine patient selection and guide treatment individualization. The future of LARC management lies in a precision-driven approach, where survival is optimized without compromising QoL. By embracing innovation and personalizing care, we are entering a new era where cure remains paramount, but never at the expense of the patient's well-being.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.915
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0060.001
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.114
GPT teacher head0.412
Teacher spread0.299 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations10
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCancer Treatment ReviewsSame topicColorectal Cancer Surgical TreatmentsFrench-language works237,207